Compare AARD & ARCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AARD | ARCL |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 178.4M |
| IPO Year | 2025 | 2025 |
| Metric | AARD | ARCL |
|---|---|---|
| Price | $5.41 | $9.99 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $15.29 | N/A |
| AVG Volume (30 Days) | ★ 134.1K | 24.0K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $9.88 |
| 52 Week High | $17.94 | $10.03 |
| Indicator | AARD | ARCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 57.18 |
| Support Level | $4.91 | $9.95 |
| Resistance Level | $6.01 | $10.02 |
| Average True Range (ATR) | 0.59 | 0.02 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 47.51 | 53.33 |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
ARC Group Acquisition I Corp is a blank check company.